key: cord-1015291-5rgikgq5
authors: Gade, Akhil R.; Alavala, Harshitha; Allam, Sridhar R.
title: Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
date: 2020-07-08
journal: Kidney Int
DOI: 10.1016/j.kint.2020.06.025
sha: 099ec8e43da2f995f3afa93760a93c4224392ae3
doc_id: 1015291
cord_uid: 5rgikgq5

nan

It is with great interest we read the article by Gautier-Vargas and colleagues that reported favorable clinical response with tocilizumab in a kidney transplant recipient with severe coronavirus disease 2019 (COVID-19) 1 . Our clinical experience has also been similar 2 . Authors reported dramatic decrease of serum interleukin 6 (IL-6) level from 430.8 pg/mL to 3.4 pg/mL within 2 days after administration of tocilizumab. However, as previously published [3] [4] , and in our own experience, IL-6 levels generally increase after administration of tocilizumab. In our published case report 2 , IL-6 level was 241 pg/mL prior to tocilizumab and it increased to 1259 pg/mL after administration of tocilizumab. Given tocilizumab functions by acting as competitive inhibitor of IL-6 receptor (IL-6R), increased serum IL-6 levels after its administration is likely caused by inhibition of IL-6R mediated clearance as well as the endogenous production of IL-6 with ongoing disease activity. Hence, we wonder if rapid decline of serum IL-6 level after tocilizumab in the case reported by Gautier-Vargas and colleagues was due to spontaneous improvement of disease activity or factors not related to tocilizumab. Randomized controlled studies are necessary to confirm the benefit of tocilizumab in transplant recipients with COVID-19.

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab

Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease